High materiality7/10
Spruce Biosciences initiated with a Buy at Guggenheim
Why it may matterVerify against the original reporting
Guggenheim initiates Buy with upside potential.
Public signal · 1-minute delayed
Signal brief
Source-backed market context you can read and share without an account.
AI summary
What happened, with direct paths to the underlying reporting
Guggenheim initiated SPRB with a Buy rating; target price $123 vs current price $49.91.
- Target: $123
- Price: $49.91
- Firm: Guggenheim
- Rating: Buy
Key facts
- 01
Target: $123
- 02
Posted price: $49.91
- 03
Analyst firm: Guggenheim
- 04
Analyst: Debjit Chattopadhyay
How to read this signal
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.